Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2011-06-22
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine, work in different ways to
stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Giving hydroxychloroquine together with bortezomib may kill more
cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of
hydroxychloroquine when given together with bortezomib and to see how well it works in
treating patients with relapsed or refractory multiple myeloma.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania University of Pennsylvania